raltegravir

Type: Keyphrase
Name: raltegravir
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Maraviroc + Raltegravir: Caution Needed

All participants were experiencing fat gain in their bodies (lipohypertrophy). On entering the study, participants had their regimens changed to the following:The study called "Roc 'n Ral" was expected to last for 48 weeks. However, an independent panel ... [Published The Body PRO - Apr 15 2014]
First reported Apr 12 2014 - Updated Apr 12 2014 - 1 reports

Merck HIV therapies make big news at CROI

NEW YORK—Two separate HIV therapies manufactured by Merck, one new and the other a groundbreaking favorite from the past, had big announcements at the 21st in early March. It was just a peek at the newcomer, doravirine (MK-1439), looking at data from ... [Published Drug Discovery News - Apr 12 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

FDA Updates Raltegravir (Isentress) Labeling

“On April 8, 2014 FDA approved updates to the Isentress (raltegravir) label to include information regarding co-adminsitration of raltegravir with boceprevir or telaprevir. “In drug interaction studies, raltegravir did not have a clinically meaningful ... [Published AIDSinfo At-a-Glance: Offering Information on H ... - Apr 11 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Starting HIV Treatment Amidst Anger and Depression

Greg FreemanIt's never an easy decision when it comes to treatment. I wasn't even sure I could accept that I was HIV positive. So many aspects of my life felt -- and were -- really uncertain. It was August 2010 when I found out that I was HIV positive. ... [Published The Body - Apr 10 2014]
First reported Apr 05 2014 - Updated Apr 05 2014 - 1 reports

Pharmacokinetic Interactions Between the HCV NS5A Inhibitor MK-8742 and Tenofovir (TDF), Raltegravir (RAL), and Efavirenz (EFV)

Pharmacokinetic Interactions Between the HCV NS5A Inhibitor MK-8742 andTenofovir (TDF), Raltegravir (RAL), and Efavirenz (EFV) CROI: - (03/06/14) - (03/10/14) Reported by Jules LevinCROI 2014 March 3-6Boston, MAWW Yeh,1 W Marshall,1 J Ma,1 E Mangin,1 ... [Published National AIDS Treatment Advocacy Project - Apr 05 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Merck : Findings from Merck & Company in the Area of HIV/AIDS Described

By a News Reporter-Staff News Editor at AIDS Weekly -- Data detailed on Immune System Diseases and Conditions have been presented. According to news reporting out of Whitehouse Station, New Jersey , by NewsRx editors, research stated, "Raltegravir (RAL) ... [Published 4 Traders - Apr 02 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Human medicines European public assessment report (EPAR): Isentress, raltegravir, Revision: 21, Authorised

This is a summary of the European public assessment report (EPAR) for Isentress. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its ... [Published European Medicines Agency - Apr 02 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

[Comment] FLAMINGO: how much rosier can antiretroviral therapy get?

In the SPRING-2 trial, dolutegravir showed non-inferiority to raltegravir, another integrase inhibitor, in antiretroviral-naive adults with HIV-1 infection. In the SINGLE trial, dolutegravir showed superiority over a non-nucleoside reverse transcriptase ... [Published The Lancet online - Apr 01 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Merck signposts a new strategy for patent owners in India

US pharmaceutical company Merck & Co – known as Merck Sharp & Dohme (MSD) outside of North America – has entered into an alliance with generic drug maker Cipla to co-market one of its antiretroviral treatments in India, Bloomberg reports. The strategy ... [Published Intellectual Asset Management - Mar 28 2014]
First reported Mar 22 2014 - Updated Mar 22 2014 - 1 reports

EFFECT OF FALDAPREVIR ON RALTEGRAVIR PHARMACOKINETICS IN HEALTHY VOLUNTEERS

Reported by Jules LevinCROI 201 March 3-6 Boston, MADavid Joseph1, Peter Rose2, Natalja Strelkowa2, Armin Schultz3, Jeanette Garcia1, Mabrouk Elgadi4, Anne-Marie Quinson1, Fenglei Huang11Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; ... [Published National AIDS Treatment Advocacy Project - Mar 22 2014]
First reported Mar 21 2014 - Updated Mar 22 2014 - 2 reports

Spine/Hip Bone Density Drops More in 96 Weeks With PIs Than With Raltegravir

21st Conference on Retroviruses andOpportunistic InfectionsBoston, MA March 3 - 6, 2014 CROI 2014, March 3-6, 2014, BostonMark MascoliniHip and spine bone mineral density (BMD) dropped significantly more during 96 weeks of first-line boosted atazanavir ... [Published National AIDS Treatment Advocacy Project - Mar 22 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 4 reports

Merck & Co. HIV Drug Strategy Seen Shielding Patent

Merck & Co. will sell the HIV medication Isentress in India by mid-year in partnership with Cipla, a move that may help the former protect its patent, Bloomberg reported Thursday. IIFL Institutional Equities analyst Bino Pathiparampil noted that "we’ll ... [Published FirstWord Pharma - Mar 20 2014]

Quotes

The research team states that the combination of maraviroc and raltegravir as dual therapy "lacks virological robustness ... and therefore cannot be recommended for further evaluation in a larger scale."
...Osinusi replied that many interferon-free studies have now suggested that HIV is not a risk factor for poorer response. "If an 8-week duration works in [HCV] monoinfected patients, I don’t see why it shouldn’t in coinfected [patients] as well" she said
The message to HIV clinicians was loud and clear: "We need to start thinking about how to integrate geriatric principles into the clinical care of our newly aging population" said Meredith Greene from the Division of Geriatrics at the University of California at San Francisco, who presented one of the studies
...According to news reporting out of Whitehouse Station, New Jersey , by NewsRx editors, research stated, "Raltegravir (RAL) is a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor approved to treat HIV infection in adults in combination with other antiretrovirals. The potential of RAL to cause transporter-related drug-drug interactions (DDIs) as an inhibitor has not been well described to date."

More Content

All (83) | News (68) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Maraviroc + Raltegravir: Caution Needed [Published The Body PRO - Apr 15 2014]
Atazanavir Resistance With Unplanned Treatment ... [Published General Medicine eJournal - Apr 15 2014]
Merck HIV therapies make big news at CROI [Published Drug Discovery News - Apr 12 2014]
FDA Updates Raltegravir (Isentress) Labeling [Published AIDSinfo At-a-Glance: Offering Information on H ... - Apr 11 2014]
EASL 2014: Sofosbuvir/Ledipasvir Produces Early... [Published HIV and Hepatitis.com - Apr 11 2014]
Starting HIV Treatment Amidst Anger and Depression [Published The Body - Apr 10 2014]
Pharmacokinetic Interactions Between the HCV NS... [Published National AIDS Treatment Advocacy Project - Apr 05 2014]
CROI 2014: Researchers Discuss HIV, Aging, and ... [Published HIV and Hepatitis.com - Apr 04 2014]
Merck : Findings from Merck & Company in the Ar... [Published 4 Traders - Apr 02 2014]
Human medicines European public assessment repo... [Published European Medicines Agency - Apr 02 2014]
Janssen Submits New Drug Application to U.S. FD... [Published Finwin - Apr 01 2014]
HIV [Published Lancet - Apr 01 2014]
[Comment] FLAMINGO: how much rosier can antiret... [Published The Lancet online - Apr 01 2014]
Osteoporosis (bone), Frailty, and Vitamin D: CR... [Published National AIDS Treatment Advocacy Project - Mar 31 2014]
Amount of foreign direct investment proves Indi... [Published Pharma Letter - Mar 31 2014]
Merck signposts a new strategy for patent owner... [Published Intellectual Asset Management - Mar 28 2014]
Multi-model inference using mixed effects from ... [Published BMC - Mar 27 2014]
The Anchor Beating HIV, buffing plants and fin... [Published Individual.com - Mar 24 2014]
EFFECT OF FALDAPREVIR ON RALTEGRAVIR PHARMACOKI... [Published National AIDS Treatment Advocacy Project - Mar 22 2014]
21st Conference on Retroviruses and Opportunist... [Published National AIDS Treatment Advocacy Project - Mar 22 2014]
Spine/Hip Bone Density Drops More in 96 Weeks W... [Published National AIDS Treatment Advocacy Project - Mar 22 2014]
CROI 2014: Inflammation in HIV.....HIV cure, co... [Published National AIDS Treatment Advocacy Project - Mar 22 2014]
In Battle of First-Line HIV Drugs, Raltegravir ... [Published The Body - Mar 21 2014]
Merck combination suppresses HCV in mono-infect... [Published Aidsmap - Mar 21 2014]
CROI 2014/APASL 2014: Merck Combo Suppresses HC... [Published HIV and Hepatitis.com - Mar 21 2014]
Merck & Co. HIV Drug Strategy Seen Shielding Pa... [Published FirstWord Pharma - Mar 20 2014]
Merck HIV drug strategy in India seen shielding... [Published Livemint.com - Mar 20 2014]
Merck's India HIV Drug Strategy May Shield Patent [Published Bloomberg - Mar 20 2014]
Merck HIV Drug Strategy Seen Shielding Patent: ... [Published Bloomberg via Google News - Mar 20 2014]
Isentress + Prezista Is Safe, Effective as Firs... [Published POZ.com - Mar 19 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FDA Updates Raltegravir (Isentress) Labeling [Published AIDSinfo At-a-Glance: Offering Information on H ... - Apr 11 2014]
“On April 8, 2014 FDA approved updates to the Isentress (raltegravir) label to include information regarding co-adminsitration of raltegravir with boceprevir or telaprevir. “In drug interaction studies, raltegravir did not have a clinically meaningful ...
[Comment] FLAMINGO: how much rosier can antiret... [Published The Lancet online - Apr 01 2014]
In the SPRING-2 trial, dolutegravir showed non-inferiority to raltegravir, another integrase inhibitor, in antiretroviral-naive adults with HIV-1 infection. In the SINGLE trial, dolutegravir showed superiority over a non-nucleoside reverse transcriptase ...
Merck HIV Drug Strategy Seen Shielding Patent: ... [Published Bloomberg via Google News - Mar 20 2014]
Merck HIV Drug Strategy Seen Shielding Patent: Corporate India Bloomberg Merck's worldwide sales of raltegravir grew about 8.5 percent to $1.6 billion in 2013, according to data compiled by Bloomberg . India had an estimated 2.1 million people living ...
3 Regimens Hold HIV in Check Without Efavirenz [Published MedPageToday.com - medical news plus CME for ph ... - Mar 08 2014]
BOSTON (MedPage Today) -- Three different regimens for treating HIV patients -- one using the twice daily integrase inhibitor raltegravir (Isentress) and two based with ritonavir-boosted protease inhibitors -- effectively suppressed the virus, researchers ...
Raltegravir Combo Gives New Anti-HIV Alternative [Published MedPageToday.com - medical news plus CME for ph ... - Mar 06 2014]
BOSTON (MedPage Today) -- The use of a two-drug anti-HIV therapy of raltegravir (Isentress) plus darunavir (Prezista) appeared to be non-inferior to tenofovir/emtricitabine (Truvada) plus darunavir, researchers reported here. ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.